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Abstract
Osteosarcoma cases with metastasis have poor prognosis in general. Recently, caffeine-
potentiated chemotherapy, which is chemotherapy with caffeine dosage against malig-
nancies, has manifested potently high efficacy as well as diverse effects. Recently, we 
demonstrated that nonionic vesicles prepared from Span 80 have promising physico-
chemical properties, which let them an attractive option besides the common liposomes. 
Here, we manifested the tumor-specific caffeine-potentiated chemotherapy against osteo-
sarcoma in murine model employing a novel drug delivery system (DDS) with Span 80 
nano-vesicles. C3H/HeJ mice underwent transplantation of LM8 osteosarcoma cell line 
and then were doped with therapeutic agents. Caffeine was employed as an enhancer in 
addition to ifosfamide (IFO) as the antitumor agent. in vitro, the united administration 
of IV + CV revealed significant induction of tumor apoptosis in the early phase. In vivo 
study manifested that IV + CV-administration markedly decreased the tumor volume as 
well as the viable tumor area than in the other groups. No marked organ damage was 
observed in the IV or IV + CV groups as well as fertility injury and/or  malformations 
in their progeny. This novel DDS might have the importance for clinical application in 
primary tumors as well as the metastatic osteosarcoma.
Keywords: DDS, Span 80 nano-vesicles, caffeine-potentiated chemotherapy, mouse 
model
1. Introduction
At present, osteosarcoma cases with metastasis, especially in lungs, have poor prognosis [1, 
2]. In recent years, caffeine-potentiated chemotherapy, which is chemotherapy with caffeine 
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dosage against malignancies, has manifested potently high efficacy [3, 4]. Nevertheless, this 
method may induce adverse effects that patients suffer, which include most commonly tachy-
cardia, nausea, psychiatric symptoms, as well as lethal arrhythmia with individual diversity 
[5]. On the other hand, there have been numerous developments in novel drug delivery sys-
tems (DDSs) for drug carriers for the treatment of various diseases that enabled target-specific 
drug delivery resulting in the prevention of side effects [6–8].
Recently, we demonstrated that nonionic vesicles prepared from Span 80 have promising 
physicochemical properties, such as high membrane fluidity associated with low-phase 
transition temperature, which make them an attractive possible alternative to the com-
monly used liposomes. Lipid vesicles have been extensively studied. Since the discovery 
of mechanism for liposome by Bangham et al. that aqueous phase of phosphatidylcholines 
includes self-closed phospholipid bilayers, which can capture and obtain water-soluble 
molecules [9], lipid vesicles have been actively investigated. Following early reports on 
vesicle formation from completely synthetic amphiphiles [10], vesicles have been prepared 
from a large number of different surfactants [11, 12]. Many vesicle systems have been 
characterized to some extent and applied in various research areas, ranging from phar-
maceuticals [12–15], food technology [12, 16, 17], and analytical applications to origin-of-
life [18, 19] and artificial cell studies [20]. Vesicles based on nonionic surfactants (so-called 
“niosomes”) [12, 21] were first used in the cosmetic industry [10, 21, 22] as alternatives to 
phospholipid-based vesicles (liposomes). One of the many surfactants used for niosome 
preparations is Span 80, a cheap, molecularly heterogeneous nonionic surfactant that is 
also applied as food emulsifier and in oral pharmaceuticals [23, 24]. Span 80 is known as 
sorbitan mono-oleate generally; nevertheless, commercially available Span 80 may be a het-
erogeneous mixture of sorbitan mono-, di-, tri, and tetra-esters which could let high fluidity 
and vascular permeability [25–27].
A successful therapeutic murine model of transplanted colon cancer employs the DDS using 
Span 80 vesicles which have immobilized polysaccharides [28]. In this chapter, we introduce 
a novel DDS by using Span 80 nano-vesicles, and manifested that tumor-specific caffeine-
potentiated chemotherapy for murine osteosarcoma using a novel DDS with Span 80 nano-
vesicles showed significant antitumor effects, as well as limited adverse effects.
2. Span 80 nano-vesicles
2.1. Characteristics of Span 80 as a material for food and pharmaceuticals
As mentioned above, Span 80 is known as sorbitan mono-oleate; nevertheless, commercially 
available Span 80 might be heterogeneous mixture, rather mainly diesters, in addition to triesters 
and tetraesters [23, 25]. Furthermore, the polar headgroup of the different esters present in Span 
80 is not sorbitol, but more likely one of the different forms of anhydrized sorbitol [29, 30], a cheap, 
molecularly heterogeneous nonionic surfactant that is also applied as food emulsifier and in oral 
pharmaceuticals [31]. The substantial molecular heterogeneity of commercial Span 80 is (i) a con-
sequence of the conditions used for the synthesis (reaction of sorbitol with fatty acids (mainly 
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oleic acid) at elevated temperature) [24, 29] and (ii) based on the fact that there are no purification 
method following the synthesis with excellent cost-performance ratio for yielding inexpensive 
products and applicable to large-scale purification. Commercially available Span 80 was deter-
mined by its molecular composition. The property of it may even be better when compared to the 
properties of the individual purified components of commercially available Span 80.
2.2. Preparation of Span 80 nano-vesicles in different forms
In our study, we prepared several variations of Span 80 vesicles as follows: Commercially 
available Span 80 was processed using the two-step emulsification method (Span 80 vesicles 
type 1), sequentially extruded by a polycarbonate membrane (Span 80 vesicles type 2) or 
ultrafiltrated (Span 80 vesicles type 3). Fractionation of commercially available Span 80 by 
chromatography into the different ester groups (see Figure 1) and vesicular preparation using 
the defined mixture of the four kinds of different ester groups (Span 80 vesicles type 4) or 
preparation from the diester fraction (Span 80 vesicles type 5) were performed [25].
2.3. Evaluation of diameter and homology by a dynamic light scattering
Vesicle characterization by dynamic light scattering (DLS) and electron microscopy was per-
formed. The different types of Span 80 vesicles prepared either in distilled water or in phos-
phate-buffered saline (PBS) solution were analyzed after vesicle preparation by dynamic light 
scattering. As expected from the different preparation methods used, the average vesicle size 
and size distribution depend on the vesicle type, independent of whether PBS or distilled 
water was used as aqueous medium. (a) The vesicle size would depend on the employed 
method; therefore, the prepared Span 80 vesicles should be kinetically trapped aggregates 
and might not have thermodynamically equilibrium structures, just like most of phosphati-
dylcholine vesicles. (b) The most homogeneous vesicles with the lowest polydispersity index 
were prepared by the extrusion method. When employing PBS as the aqueous medium, the 
size of Span 80 vesicle type 1 with an apparent size of 250 ± 45 nm, which was obtained by 
DLS, could be reduced into 105 ± 13 nm by extrusion through polycarbonate membranes with 
a nominal pore diameter of 100 nm. Extrusion method enabled to make more homogeneous 
vesicles with less polydispersity index. Span 80 vesicles type 2 manifested the appropriate 
diameter (c.a. 100 nm) for the drug delivery; therefore, these types of vesicles were employed 
for further analyses in the development of DDS.
2.4. Evaluation of diameter and physicochemical property by electron microscopy
Span 80 vesicles type 2 (100 nm) prepared in PBS was also statistically analyzed by cryo-transmis-
sion electron microscopy (cryo-TEM, Figure 1A), yielding a number-weighted average vesicle 
size of 63. This value is lower than the z-average value (scattering intensity weighted) deter-
mined by DLS. Next, the hydrodynamic diameter was evaluated; on the other hand, in cryo-TEM 
images, the projected, “true” size of a spherical vesicle was obtained. The discrepancy among 
these methods could be addressed that the electron dense headgroup area made vesicles more 
boundary. Conclusively, electron microscopy revealed the diameter and bilayer thickness of the 
vesicles by Cryo-TEM, as well as the presence of uniformity of the vesicles by freeze  fracture 
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Figure 1. Electron microscopic analysis of Span 80 vesicles type 2 (100 nm), prepared in PBS. (A) Cryo-TEM micrographs 
showing unilamellar- and bilamellar vesicles and bilayer fragments (arrow). Length of the bar: 100 nm. Freeze fracture 
(B) and negative-staining (C) electron micrographs of Span 80 vesicles type 2 (100 nm), prepared in PBS solution. Length 
of the bar: 100 nm. The arrow in C points to one of the fragments present. [Reprinted with permission from Ref. [25]. 
Copyright (2008) American Chemical Society].
The Question of Caffeine110
scanning electron microscopy (Figure 1). Electron micrographs revealed that Span 80 vesicle sus-
pensions contain not only vesicles but also bilayer fragments. The clear contrast was observed 
among 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) or dioleoylphosphatidylcho-
line (DOPC) vesicles which might be due to the molecular heterogeneity of Span 80 vesicles.
2.5. Temperature sensitivity of Span 80 vesicles
The temperature sensitivity of Span 80 vesicles might not link directly to the T
m
 value, because 
the observed fusion phenomenon did not develop at T
m 
as the temperature-sensitive vesicles 
based on 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) [32]. In DPPC-based vesicles, 
the thermos-responsive effect is the leakage of the aqueous contents when the temperature 
reaches T
m
 [33].
The Span 80 vesicles develop fusion in response to an increase in temperature. Therefore, the 
molecular mechanisms of thermos-response in each kind of vesicles are different. The pres-
ence of bilayer fragments in fused Span 80 vesicles at an elevated temperature is not clear at 
this moment. However, the nonionic headgroup in Span 80 could be dehydrated and result in 
vesicle-vesicle aggregation and fusion at the temperature above T
m
.
2.6. Vesicle membrane fusion property
The vesicle fusion property may be advantageous for efficient drug delivery, and applications 
of the several types of Span 80 vesicles described and characterized in this chapter, and previ-
ous papers largely depend on the vesicle’s cytotoxicity. Although previous studies of Span 
80-based vesicles regarding cytotoxicity either as a drug carrier or as a gene vector were suc-
cessful, further studies have been required before any conclusions with respect to pharmaceu-
tical applications [25] can be drawn. Among the various types of Span 80 vesicles investigated, 
Span 80 vesicles type 2 (100 nm) might be the most attractive one (straightforward methodol-
ogy with the requirement of simple equipment only).
3. Caffeine-potentiated chemotherapy using Span 80 nano-vesicles’ DDS
We developed the murine osteosarcoma therapeutic model of caffeine-potentiated chemother-
apy. In this model, as the therapeutic agents, ifosfamide (IFO) was employed as well as caffeine 
sodium benzoate (CSB) as an enhancer. As the murine osteosarcoma therapeutic model, C3H/
HeJ mice underwent transplanted murine osteosarcoma cell line LM8. The detailed procedures 
were described in the original paper [34].
3.1. Preparation of Span 80 nano-vesicles
Span 80 nano-vesicles, which contained IFO and/or caffeine, were freshly prepared as previously 
described [28]. Briefly, materials for assembling nano-vesicles containing Span 80 and Tween-80 
[35], cholesterol, which worked as the stabilizer of the membrane, polyethylene glycol, used as a 
stealth modifier against macrophages [28], and the solvents, normal hexane and normal saline, 
were purchased, respectively. All processes were performed under sterilized conditions.
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The two-step emulsification method was employed to process and purify the nano-vesicles. Span 
80 and cholesterol were dissolved in hexane by homogenization with a micro-homogenizer in a 
sterilized brown glass bottle. Sequentially, the first emulsion was prepared by adding IFO and/
or CSB, which dissolved in normal saline into the Span 80 material followed by homogenization. 
As a negative control, phosphate-buffered saline was dripped alternatively. The second-stage 
emulsion was processed by evaporation using a rotary vacuum evaporator on a water bath at 
37°C followed by homogenization with Tween-80.
The second emulsion was centrifuged using ultra-centrifugation equipment. After aspiration 
of the supernatant, the sediment of the Span 80 vesicles was weighed and then suspended in 
normal saline at a concentration of 20% w/v. By this method, IFO Span 80 vesicles (IV), CSB 
Span 80 vesicles (CV), and PBS-alone Span 80 vesicles (PV) were prepared. Immediately before 
the use in vivo or in vitro, these suspensions became extruded by a custom-made extruder with 
a drain disk of 100-μm thickness and a Nucleopore membrane® of 100-nm pore size to control 
the vesicular size. As a result, the diameter of the vesicles was evaluated by the dynamic light-
scattering device and revealed 117 nm at average.
3.2. In vitro evaluation of the antitumor effects of the nano-vesicles
The murine osteosarcoma cell line, LM8, was obtained and employed as an osteosarcoma 
model. LM8 cells in Dulbecco's modified Eagle's medium were plated and cultured in 24-well 
culture dishes for a few days until the cells showed semi-confluent state. Next, antitumor 
agents with or without Span 80 vesicles, including PV, IV, CV, direct administration of IFO 
or CSB, as well as the combination of IV + CSB, IFO + CV and IV + CV were administered. 
Cells were incubated with the antitumor agents at 37°C for 1 or 2 h, and then the cells were 
harvested and evaluated for apoptosis and cell viability, respectively.
In vitro analyses revealed cultured LM8 murine osteosarcoma cells with IV + CV almost com-
plete cell death by the trypan blue assay, on the other hand, PBS, CSB, PV, and CV manifested 
almost no cell death. IFO resulted in 13%, IV resulted in 28%, and IFO + CV resulted in 75% 
cell death (Figure 2 and Table 1).
3.3. Apoptosis detection by propidium iodide (PI) method
Briefly, cells were suspended in ice-cold Hank's balanced saline solution (HBSS), followed 
by fixation with 70% EtOH at −20°C [36]. Fixed cells were centrifuged, then pellets were 
 re- suspended in extraction buffer of pH 7.8 which contained Na
2
HPO
4
, citric acid, and 0.1% 
Triton X-100 at 37°C. Then, a staining solution of pH 6.8 containing PIPES, NaCl, Mg
2
Cl, Triton 
X-100, PI, and 50 RNAse H was added to the cell suspension, and the fluorescence intensity 
was evaluated and analyzed in triplicate by the FACStation® and CellQuest® software.
PI analyses revealed that almost cell population (97%) underwent apoptotic cell death, which 
treated with IV + CV. By contrast, PBS, CSB, PV, and CV conducted cell death in very limited 
population, while IFO and IV let the small population into apoptosis and/or necrosis (8.8–
10.2%), as well as IFO + CSB and IV + CSB induced increasing cell death to approximately a 
quarter to one-third of the population (Figure 3 and Table 2).
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3.4. Murine osteosarcoma therapeutic model
For the therapeutic model, C3H/HeJ mice were employed because they are H2-matched to 
LM8 osteosarcoma cell line since this cell line was originated from that strain of mouse [37]. 
LM8 cells (3.0 × 106 cells per mice) were subcutaneously transplanted into 6-week-old male 
Figure 2. Representative photomicrographs of the trypan blue-stained LM8 cells after a 2-h incubation with antitumor 
agents: (A) PV, (B) CV, (C) IFO, (D) IV, (E) IFO + CV, and (F) IV + CV. [Reprinted with permission from Ref. [34]. 
Copyright (2014) Spandidos Publications].
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Treatment Population of nonviable cells (%) (mean ± SD)
PBS 1.5 ± 0.9
CSB 2.1 ± 1.2
PV 3.3 ± 1.8
CV 3.1 ± 1.9
IFO 13 ± 3.4a
IV 28 ± 5.5a
IFO + CSB 25 ± 6.7b
IV + CSB 40 ± 9.2c
IFO + CV 75 ± 10.8d
IV + CV 98 ± 1.2e
aP < 0.05 versus PBS, CBS, PV, and CV.
bP < 0.05 versus PBS, CSB, PV, CV, and IFO.
cP < 0.01 versus IFO, P < 0.05 versus IV and IFO + CSB.
dP < 0.01 versus IV + CSB and the other groups
eP < 0.05 versus IFO + CV, P < 0.01 versus the other groups.
Table 1. Nonviable cell population in trypan blue analysis.
C3H/HeJ mice. After c.a. 3 weeks, when the tumor volume reached up to 500 mm3, injection 
of the therapeutic agents was started. The administration protocol is schemed in Figure 4.
The agents were administered individually or in combinations as follows: PBS (i.v., sham 
administration), CV (0.1 mg/g BW), IFO (direct i.v. 0.1 mg/g BW), IV (i.v. 0.1 mg/g BW), IV 
+ CSB, and IV + CV. Five to eight animals in each groups were analyzed in the study. The 
therapeutic agents were intravenously administered via tail vein on days 0, 2, and 4, followed 
by the harvest under anesthesia on day 7. Tumor diameter as well as the body weight of 
each individual was measured every day. At the time of the harvest, volumes and weights of 
tumors were evaluated; subsequently, the entire organs and the tumors were processed for 
histopathological analyses.
No significant differences were noted in body weights among each other in the groups. It was 
marked that the tumor volumes in the IV + CV group were reduced as compared to those of 
the control groups (PBS and CV), as well as a tendency toward a decrease against the PV- and 
IFO-direct i.v. groups on days 5–7 (Figure 5) could be shown.
3.5. Histopathological analyses
The histopathological analyses of the harvested tumors and entire organs were executed on 
the formalin-fixed, paraffin-embedded tissue section. The area of viable tumor was evaluated 
as the viability of the tumor tissue in hematoxylin-eosin (HE)-stained sections. Next, in order 
to determine the adverse effects, entire organ tissue sections stained with HE, periodic acid-
Schiff (PAS), and Elastica-Goldner stains were accessed by skilled pathologists.
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IFO, IV, IV + CSB, and IV + CV groups revealed significantly smaller viable tumor areas in 
comparison to the controls. Moreover, the IV + CV group revealed markedly reduced viable 
tumor areas against the IFO and IV groups (Figures 6 and 7).
3.6. Histopathological analyses for adverse effects in vivo
To determine whether the DDS using Span 80 vesicles could prevent or reduce haz-
ardous adverse effects due to the chemotherapeutic agents, the entire organs were 
 histopathologically examined. Marked prevention of adverse effect was histopathologically 
Figure 3. The PI-staining apoptosis assay using flow cytometry. Each panel shows the event count (vertical axis) at each 
intensity (horizontal axis). The population of apoptotic and/or necrotic cells was measured as M1 and was shown in 
Table 2. [Reprinted with permission from Ref. [34]. Copyright (2014) Spandidos Publications].
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observed in the kidney, liver, and testis. Significant tubular injury, which was recognized as a 
loss of brush border, as well as the glomerular damages such as the expansion of the mesan-
gial matrix was manifested in the IFO-direct i.v. group in contrast to those in the IV and/
or IV+CV groups (Figure 8A and B). Furthermore, in the liver, spotty or grouping necrosis 
as well as reduced glycogen storage in the hepatocytes was observed in the IFO-direct i.v. 
groups in contrast to those in the IV and IV + CV groups (Figure 8C and D). Moreover, the IV 
and IV + CV groups manifested no remarkable changes in spermatogenesis, while the IFO-
direct i.v. group revealed marked suppression of spermatogenesis along with the necrosis of 
the germ cells (Figure 8E and F).
3.7. Fertility test
In order to elucidate whether the DDS with Span 80 nano-vesicles could be able to prevent the 
infertility, fertility tests were performed. Three male C3H/HeJ mice in each group that were 
administered IFO, IV, or IV + CV were cross-mated with 6-week-old female C3H/HeJ mice 
individually; then the fertility of each male was evaluated.
Treatment Population of nonviable cells (%) (mean ± SD)
PV 1.6 ± 1.1
CV 1.4 ± 1.0
IFO 8.8 ± 1.9a
IV 10.2 ± 2.9a
IFO + CSB 16.5 ± 3.9b
IV + CSB 25.2 ± 4.2b
IFO + CV 32.8 ± 5.9b
IV + CV 97.1 ± 1.9c
aP < 0.05 versus PV and CV.
bP < 0.05 versus PV and CV.
cP < 0.001 versus PV and CV.
Table 2. Population of nonviable cells (M1) in flow cytometry.
Figure 4. The in vivo therapeutic model. Administration of the antitumor agents was initiated when the tumor volume 
reached ~500 mm3 (day 0), and continued on days 2 and 4. Then the mice were sacrificed and analyzed on day 7. 
[Reprinted with permission from Ref. [34]. Copyright (2014) Spandidos Publications].
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Figure 5. Trace of tumor volumes after antitumor agent administration. The symbols represent the mean value of 
each group, and the bars represent standard deviation. [Reprinted with permission from Ref. [34]. Copyright (2014) 
Spandidos Publications].
Figure 6. Representative photomicrographs of the tumors treated with (A) CV, (B) IFO, (C) IV, and (D) IV + CV. 
[Reprinted with permission from Ref. [34]. Copyright (2014) Spandidos Publications].
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The test revealed that the male mice after IV + CV administration had normal fertility, and 
there were no malformations in their progeny.
4. Discussion and conclusion
A promising suggestion from the therapeutic model of the DDS with Span 80 vesicles was 
conducted that this DDS could enhance the therapeutic effects of IFO and caffeine-potenti-
ated IFO chemotherapy, over and above prevent the hazardous adverse effects induced by 
chemotherapy. In vitro studies revealed drastic cell death in a very early phase by IV + CV 
administration in contrast to the “mild” apoptotic cell death inference by the administration 
of IFO alone, IV alone, or combinations of IFO + CSB, IV + CSB, and IFO + CV. These findings 
suggested that the immediate delivery of therapeutic agents into the cytosol by IV + CV addi-
tion might induce extremely rapid apoptosis. Fusion of Span 80 vesicles and cell membrane 
could be implicated in this rapid response; nevertheless, the comprehensive mechanisms are 
still unknown.
Marked development of the DDS employing nano-vesicles has been reported along with the 
development of many types of phospholipids and/or detergents [6–8, 38]. The Span 80 nano-
vesicle might be a promising material among them, based on its favorable physicochemical 
properties, including membrane fluidity and flexibility. With respect to membrane fluidity, 
Hayashi et.al. reported that Span 80 vesicles have markedly high fluidity with various cho-
lesterol contents in comparison to conventional phospholipid liposomes, such as 1,2-dipal-
mitoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
liposomes. Not only the high fluidity, also Span 80 vesicles manifest much more flexibility in 
comparison to DPPC and POPC liposomes [26].
Figure 7. The nonviable tumor area (%) in each animal from each group. The center bars express mean value, as well 
as the upper and lower bars express standard deviation. [Reprinted with permission from Ref. [34]. Copyright (2014) 
Spandidos Publications].
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Nonvesicular aggregates are observed often in the common liposome suspensions; on the 
other hand, Span 80 vesicle suspensions also could contain limited amount of nonvesicular 
aggregates such as tubulin structures. Recently, Kato et al. manifested that the Span 80 nano-
vesicle might be a kind of kinetically trapped aggregates and might not have thermodynamic 
equilibrium structures, like in most kinds of vesicles prepared from phosphatidylcholines 
(liposomes) [25].
Figure 8. Representative histopathological characteristics of the renal tissue (A and B), liver (C and D), and testis (E and 
F), which were harvested from the animals with IV+CV (A, C, and E) and IFO i.v. (B, D, and F) administration.
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The adverse effects induced by ifosfamide have been reported in kidney [35, 39–42], liver 
[43–45], gonadal cells [46–48], and bone marrow more frequently to other organs [49, 50]. 
In the therapeutic model of Span 80 DDS, the mice in the IFO-direct i.v. group also mani-
fested moderate tubular injury as well as the glomerular damage in kidney, moreover, severe 
inhibition of spermatogenesis with gonadal cell necrosis. On the other hand, the novel DDS 
employing Span 80 nano-vesicles manifested marked prevention of the hazardous adverse 
effects in the kidney, liver, and testis. These favorable results could implicate the tumor 
selectivity of the Span80 vesicles, which might be at least partially resulting from the refrain-
ing from phagocytosis taken on the pegylation of the vesicles and also possibly on the lower 
permeability at the blood-testis barrier in comparison to the direct injection of low-molecu-
lar-weight molecules such as IFO [48, 51].
The results of our study indicated that higher vascular permeability and inclination to fuse 
with the instable cell membrane of the tumors based on high fluidity and flexibility as well 
as pegylation could result in the higher tumor selectivity of Span 80 vesicles [52]. Recently, 
a cell fusion model using Span 80 vesicles has been reported [27]. Furthermore, our results 
manifested that CV conducted markedly better enhancement of antitumor effects than that 
of the direct injection of CSB. This might be addressed by the pegylation-associated tumor 
selectivity as well as the inclination for cell fusion which might enable the immediate caf-
feine delivery into the cytoplasm. Moreover, the prevention of caffeine toxicity, which causes 
the withdrawal of numerous patients from caffeine-potentiated chemotherapy, could be pre-
vented based on the selectivity of caffeine delivery by using Span 80 vesicles [5]. Currently, 
a DDS of doxorubicin containing liposomal nano-vesicles is applied in actual cancer therapy 
with marked efficacy [6–8, 53–55]. The next-generation liposomes with membrane-bound-tar-
geting molecules have also been under development. An anticarcinoma application of Span 
80 vesicles containing doxorubicin with or without membrane-bound-targeting molecule was 
recently reported [52]. As described above, Span 80 has favorable physicochemical proper-
ties; moreover, it also confirmed risk-free information because it has been already used as a 
stabilizer for injected drugs. Furthermore, the cost of Span 80 vesicles should be drastically 
cheaper than common liposomes. Therefore, the DDS with Span 80 nano-vesicles might be a 
promising next-generation DDS.
Recently, a novel treatment method for lymph node metastasis using a lymphatic drug deliv-
ery system with nano-/microbubbles has been advocated [56–58]. Those reports suggested 
that the lymphatic DDS might drastically improve the tissue selectivity and response rates to 
the metastatic tumors which had been limited in the hematogenous administration of drugs 
resulting in poor prognosis. Furthermore, those models could prevent the systemic toxic 
effects of the treatment; nevertheless, they employed highly toxic doxorubicin as the antitu-
mor agent. The caffeine-potentiated chemotherapy employing the DDS with Span 80 vesicles 
might have excellent affinity to this lymphatic administration and more effective and less 
harmful treatment onto the tumor with lymph-nodal metastasis.
In conclusion, the DDS with Span 80 vesicles may enhance the antitumor effects of IFO and 
of caffeine-potentiated IFO chemotherapy against osteosarcoma. Moreover, the usage of this 
DDS may suppress the adverse effects, which were induced by the chemotherapy. Thus, this 
The Question of Caffeine120
DDS model has promising importance for clinical application in the therapy of metastatic 
osteosarcoma as well as the primary tumors.
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